Move to the main content
Master & PhD Program in Biotechnology Industry

Master & PhD Program in Biotechnology Industry
:::
Jau-Song Yu

Jau-Song Yu

JobTitle： Professor

CurrentJob： Director of Molecular Medicine Research Center

E-mail： yusong@mail.cgu.edu.tw

Phone： 5171

Education： National Tsing Hua University, Institute of Life Sciences

Expertise： Signal Transduction, Proteomics, Cancer biomarker

Website： https://orcid.org/0000-0002-4295-983X

Research Direction

Research interests:
The research interests in my lab are to apply multi-omics approaches (genomics,
transcriptomics, proteomics and metabolomics) to explore cancer biomarkers for early
detection and to investigate novel cellular signaling networks in cell/cancer biology.
Specific topics include: 
1. Multiomic analysis of oral squamous cell carcinoma (OSCC). OSCC is a
common cancer worldwide that represents a serious and growing problem in
many parts of the globe, including Taiwan. However, little improvement has been
made for the early detection and targeted therapy of OSCC in the past decades.
Our lab leads the Molecular Medicine Research Center (MMRC) OSCC research
team to participate in the International Cancer Proteogenome Consortium (ICPC),
which is a part of international Cancer Moonshot program led by National Cancer
Institute, USA. We apply the multi-omics approach to systemically analyze OSCC
specimens (cancer tissues and adjacent non-tumor parts) using genomics (WES
and Rseq), proteomics/phosphoproteomics, and metabolomics technology
platform established in the MMRC, Chang Gung University. We hope to establish
the first Taiwanese OSCC multi-omics blueprint which can greatly facilitate the
discovery of new biology of OSCC, as well as the identification new biomarkers
and/or therapeutic targets for early detection and effective treatment of OSCC.
     
 
(2) R & D of clinically applicable cancer biomarkers. Cancer is one of the major
death cause in the world, and delayed diagnosis of cancer represents the main reason
of high mortality rate of many cancer types. We put efforts to discover cancer
biomarkers from tissues, body fluids and cell lines and their verification in clinical
specimens using proteomics technology platforms established in the Chang Gung
University Proteomics Core Lab. We focus on four cancer types: OSCC, colorectal,
pancreatic and liver cancers. Our long-term goal is to develop clinically useful
biomarkers for early detection of cancer, which are expected to significantly improve
human health (better patient outcome and less treatment cost). Currently, the major
research outcomes for OSCC salivary biomarkers have been published
in 2016/10 and 2020/8, respectively, from which a patent for OSCC detection method
has been approved by several countries and transferred to a local biotech company for
subsequent development of commercial assays (ELISA and rapid test). The
product “Immuno-based Rapid Test for Detecting the Oral Cancer Biomarker-OCBM-1”
derived from this Industry-university collaboration effort has been awarded the “2019
Taipei Biotech Awards – Technology Transfer Special Mention Award”. The OCBM-1

ELISA kit has obtained European CE marking (registration No. 00159706) on 2020/12,
representing the first commercial ELISA kit invented from Taiwan for detecting oral
cancer biomarker using saliva specimens. Additionally, the major research outcome for
pancreatic cancer blood biomarker has been published in 2011/05, from which a patent
for pancreatic cancer detection method has been approved by several countries and
transferred to a local biotech company for subsequent development of commercial
assays.
(3) Development of aptamer for medically important proteins. Aptamer is a kind of
single chain RNA or DNA with unique 3D structure that can selectively bind to a specific
target (proteins, peptides, carbohydrates, small molecules, toxins, and even live cells).
Aptamer can be produced using an in vitro, PCR-based selection method called SELEX
(systematic evolution of ligands by exponential enrichment), displaying high potential as
a molecular tool for medically important targets. Our lab has established a high
throughput SELEX platform for selecting DNA aptamers against different proteins. We
focus on proteins with important clinical relevance or research utility, such as virus
protein, snake venom protein, cancer biomarker, etc.

Publications

Papers published in the past five years：*corresponding author

  1. ●● Dash S†, Wu CC†, Wu CC, Chiang SF, Lu YT, Yeh CY, You JF, Chu LJ, Yeh TS, Yu JS*. (2023) Extracellular vesicle membrane protein profiling and targeted mass spectrometry unveil CD59 and tetraspanin 9 as novel plasma biomarkers for detection of colorectal cancer. Cancers (Basel) 2023, 15, 177. [Link]
  2. Tsai TY, Kao HK, Huang Y, Chang YT, Young CK, Hung SY, Chang YS, Yu JS, Chang KP*. (2022) Plasma matrix metalloproteinase-1 as a prognostic biomarker in oral cavity squamous cell carcinoma. Cancer Management and Research. 14: 3459–3468 [PubMed]
  3. Lin CC*, Shih CP, Wang CC, Ouyang CH, Liu CC, Yu JS, Lo CH. The clinical usefulness of Taiwan bivalent freeze-dried hemorrhagic antivenom in Protobothrops mucrosquamatus- and Viridovipera stejnegeri-envenomed patients. Toxins (Basel). 2022 Nov 15;14(11):794. doi: 10.3390/toxins14110794. [PubMed]
  4. Chen CH, Wei KC, Liao WC, Lin YY, Chen HC, Feng LY, Liu CH, Huang CY, Chen KT, Wu CS, Chang YS, Yu JS, Chang IY*. (2022) Prognostic value of an APOBEC3 deletion polymorphism for glioma patients in Taiwan. Journal of Neurosurgery 2022 Sep 23;1-13. doi: 10.3171/2022.7.JNS2250. Online ahead of print. [PubMed]
  5. Chen H, Zhang S, Jin S, Hsiao YC, Wang Q, Yu JS, Li W*. (2022) Graphene oxide and fluorescent-aptamer-based novel aptasensors for detection of metastatic colorectal cancer cells. Polymers 2022 Jul 27;14(15):3040. doi: 10.3390/polym14153040. [PubMed]
  6. Wang PY, Chakraborty A, Ma HJ, Wu JW, Jang AC, Lin WC, Pi HW, Yeh CT, Cheng ML, Yu JS, Pai LM*. (2022) Drosophila CTP synthase regulates collective cell migration by controlling the polarized endocytic cycle. Development 2022 Aug 15;149(16):dev200190. doi: 10.1242/dev.200190. Epub 2022 Aug 22. [PubMed]
  7. Chen YT, Kan CH, Liu H, Liu YH, Wu CC, Kuo YP, Chang IY, Chang KP, Yu JS, Tan BC*. (2022) Modular Scaffolding by lncRNA HOXA10-AS Promotes Oral Cancer Progression. Cell Death Dis 2022 Jul 20;13(7):629. doi: 10.1038/s41419-022-05071-6. [PubMed]
  8. Liu CC#, Wu CJ#, Chou TY, Liaw GW, Hsiao YC, Chu LJ, Lee CH, Wang PJ, Hsieh CH, Chen CK*, Yu JS*. (2022) Development of a monoclonal scFv against cytotoxin to neutralize cytolytic activity induced by Naja atra venom on myoblast C2C12 cells. Toxins 2022 Jul 4;14(7):459. doi: 10.3390/toxins14070459. [PubMed]
  9. Yang CK#, Hsu HC#, Liu YH, Tsai WS, Chen YT, Huang SF, Tan BCM, Chang IYF, Yang C, Yang CY, Yu JS, Liu H*. (2022) EV-miRome-wide profiling uncovers miR-320c for detecting metastatic colorectal cancer and monitoring the therapeutic response. Cellular Oncology (Dordr). 2022 Aug;45(4):621-638. doi: 10.1007/s13402-022-00688-3. Epub 2022 Jul 18. [PubMed]
  10. ● Li W, Wu CC, Wang S, Zhou L, Qiao L, Liu F, Zhan L, Chen H, Yu JS*, Fang J*. (2022) Identification of the target protein of the metastatic colorectal cancer-specific aptamer W3 as a biomarker by aptamer-based target cells sorting and functional characterization. Biosensors and Bioelectronics 2022 Jun 3; 213:114451. doi: 10.1016/j.bios.2022.114451. Online ahead of print. [PubMed]
  11. Wu CP*, Hung CY, Murakami M, Wu YS, Lin CL, Huang YH, Hung TH, Yu JS, Ambudkar SV. (2022) P-glycoprotein Mediates Resistance to the Anaplastic Lymphoma Kinase Inhiitor Ensartinib in Cancer Cells. Cancers (Basel). 2022 May 9;14(9):2341. doi: 10.3390/cancers14092341. [PubMed]
  12. Yen WC, Chang IYF, Chang KP, Ouyang CN, Liu CR, Tsai TL, Zhang YC, Wang YH, Yu AL, Liu H, Wu CC, Chang YS, Yu JS, Yang CY*. (2022) Genomic and molecular signatures of successful patient-derived xenografts for oral cavity squamous cell carcinoma. Frontiers in Oncology 2022 Apr 4;12:792297. doi: 10.3389/fonc.2022.792297. eCollection 2022. [PubMed]
  13. Wu YY#, Hsieh IS#, Tung CH, Weng CH, Wu JE, Yu JS, Hong TM*, Chen YL*. (2022) A novel DNA aptamer targeting lung cancer stem cells exerts a therapeutic effect by binding and neutralizing Annexin A2. Molecular Therapy-Nucleic Acids. 2022 Jan 19;27:956-968. doi: 10.1016/j.omtn.2022.01.012. eCollection 2022 Mar 8. [PubMed]
  14. ● Liu CC, Hsiao YC, Chu LJ, Wang PJ, Liu CH, Hsieh WC, Yu JS*. (2021) Development of antibody detection ELISA based on immunoreactive toxins and toxin-derived peptides to evaluate the neutralization potency of equine plasma against Naja atra in Taiwan. Toxins 2021 Nov 19;13(11):818. doi: 10.3390/toxins13110818. [PubMed]
  15. Hsieh YJ, Chien KY, Chang CM, Hung CY, Li L, Chiang WF, Lee CC, Chang CH, Chang YH, Yu JS*, Chen YT*. (2021) Development of a method for dansylation of metabolites using organic solvent-compatible buffer systems for amine/phenol submetabolome analysis. Analytica Chimica Acta 2022 Jan 2;1189:339218, Available online 27 October 2021 [PubMed]
  16. Lai MC*, Chen YP, Li DA, Yu JS, Hung HY, Tarn WY*. (2021) DDX3 interacts with USP9X and participates in deubiquitination of the anti-apoptotic protein MCL1. FEBS J. 2022 Feb;289(4):1043-1061. doi: 10.1111/febs.16219. Epub 2021 Oct 11.[PubMed]
  17. Wu CC#, Lu YT#, Yeh TS#, Chan YH, Dash S, Yu JS* (2021) Fucosylated SERPINA1 is a novel serum marker for pancreatic cancer revealed by lectin affinity capture coupled with iTRAQ-based quantitative glycoproteomics approach. Int J Mol Sci 2021 Jun 4; 22(11), 6079. doi: 10.3390/ijms22116079. [PubMed]
  18. ● Liu JC, Chen YT, Hsieh YJ, Wu CC, Huang MC, Hsu YC, Wu CT, Chen CK, Dash S, Yu JS* (2021) Association of urinary ketamine and APOA1 levels with bladder dysfunction in ketamine abusers revealed via proteomics and targeted metabolite analyses. Scientific Reports 2021 May 5;11(1):9583. doi: 10.1038/s41598-021-89089-4. [PubMed]
  19. Chiang SF+, Huang HH+, Tsai WS+, Tan BCM, Yang CY, Huang PJ, Chang IYF, Lin J, Lu PS, Chin E, Liu YH, Yu JS, Chiang JM, Hung HY, You JF, Liu H*. (2021) Comprehensive functional genomic analyses link APC somatic mutation and mRNA-miRNA networks to the clinical outcome of stage-III colorectal cancer patients. Biomedical Journal Available online 16 March 2021. doi: 10.1016/j.bj.2021.03.001
  20. Wu CP*, Hung CY, Lusvarghi S, Chang YF, Hsiao SH, Huang YH, Hung TH, Yu JS, Ambudkar SV (2021) Overexpression of human ABCB1 and ABCG2 reduces the susceptibility of cancer cells to the histone deacetylase 6-specific inhibitor citarinostat. Int J Mol Sci 2021 Mar 5; 22(5), 2592. doi: 10.3390/ijms22052592. [PubMed]
  21. Liu CC#, Yang YH#, Hsiao YC, Wang PJ, Liu JC, Liu CH, Hsieh WC, Lin CC, Yu JS* (2021) Rapid and efficient enrichment of snake venoms from human plasma by a strong cation exchange tip column to improve snakebite diagnosis. Toxins 2021 Feb 13; 13(2), 140. doi: 10.3390/toxins13020140. [PubMed]
  22. ●● Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IYF, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS*. (2020) Verification of saliva matrix metalloproteinase-1 as a strong diagnostic marker of oral cavity cancer. Cancers (Basel). 2020 Aug 13; 12(8):E2273. doi: 10.3390/cancers12082273. [PubMed]
  23. Chen YT#, Chang IYF#, Kan CH, Liu YH, Kuo YP, Tseng HH, Chen HC, Liu H, Chang YS, Yu JS, Chang KP, Tan BCM*. circRNAome profiling unveils a novel oncogenic circFLNB circuit in oral cancer. (2020) Cells. 2020 Aug 10; 9(8):E1868. doi: 10.3390/cells9081868 [PubMed]
  24. ● Lin YH*, Wu CC, Su WT, Tseng PC, Hsueh YY, Hsiao YC, Chang KP, Yu JS*, Chuang YR. (2020) Target peptide enrichment microfluidic chip for rapid detection of oral squamous cell carcinoma using stable isotope standards and capture by anti-peptide antibodies. Sensors and Actuators B: Chemical 2020 Nov 1, 322:128607
  25. Wu CP*, Hung CY, Lusvarghi S, Huang YH, Tseng PJ, Hung TH, Yu JS, Ambudkar SV. (2020) Overexpression of ABCB1 and ABCG2 contributes to reduced efficacy of the PI3K/mTOR inhibitor samotolisib (LY3023414) in cancer cell lines. Biochemical Pharmacology 2020 Jul 4:114137. doi: 10.1016/j.bcp.2020.114137. [PubMed]
  26. Hsueh PC, Wu KA, Yang CY, Hsu CW, Wang CL, Hung CM, Chen YT, Yu JS, Wu CC* (2020) Metabolomic profiling of parapneumonic effusion reveals a regulatory role of dipeptides in interleukin-8 production in neutrophil-like cells. Analytica Chimica Acta 2020 Sep 1;1128:238-250. doi: 10.1016/j.aca.2020.06.022. [PubMed]
  27. Chakraborty A, Lin WC, Lin YT, Huang KJ, Wang PY, Chang YF, Wang HI, Ma KT, Wang CY, Huang XR, Lee YH, Chen BC, Hsieh YJ, Chien KY, Lin TY, Liu JL, Sung LY, Yu JS, Chang YS, Pai LM*. (2020) SNAP29 mediates the assembly of histidine-induced CTP synthase filaments in proximity to the cytokeratin network. J Cell Sci 2020 May 11;133(9):jcs240200. doi: 10.1242/jcs.240200. [PubMed]
  28. Hsiao TF#, Wang CL#, Wu YC, Feng HP, Chiu YC, Lin HY, Liu KJ, Chang GC, Chien KY, Yu JS, Yu CJ*. (2020) Integrative omics analysis reveals soluble cadherin-3 as a survival predictor and an early monitoring marker of EGFR tyrosine kinase inhibitor therapy in lung cancer. Clin Cancer Res. 2020 Jul 1;26(13):3220-3229. doi: 10.1158/1078-0432.CCR-19-3972. [PubMed]
  29. Liu CC#, Chou YS#, Chen CY, Liu KL, Huang GJ, Yu JS, Wu CJ, Liaw GW, Hsieh CH*, Chen CK*. (2020) Pathogenesis of local necrosis induced by Naja atra venom: Assessment of the neutralization ability of Taiwanese freeze-dried neurotoxic antivenom in animal models. PLOS Neglected Tropical Diseases. 2020 Feb 7;14(2):e0008054. doi: 10.1371/journal.pntd.0008054. [PubMed]
  30. ●● Hsiao YC, Lin SY, Chien KY, Chen SF, Wu CC, Chang YT, Chi LM, Chu LJ, Chiang WF, Chien CY, Chang KP, Chang YS, Yu JS* (2020) An immuno-MALDI mass spectrometry assay for the oral cancer biomarker, matrix metalloproteinase-1, in dried saliva spot samples. Anal Chim Acta 1100:118-130. doi: 10.1016/j.aca.2019.12.006. [PubMed]
  31. ● Chi LM#, Hsiao YC#, Chien KY#, Chen SF, Chuang YN, Lin SY, Wang WS, Chang IYF, Yang C, Chu LJ, Chiang WF, Chien CY, Chang YS, Chang KP*, Yu JS*. (2020) Assessment of candidate biomarkers in paired saliva and plasma samples from oral cancer patients by targeted mass spectrometry. J Proteomics. 2020 Jan 16;211:103571. doi: 10.1016/j.jprot.2019.103571. [PubMed]
  32. Lin WR*, Chiang JM, Lim SN, Su MY, Chen TH, Huang SW, Chen CW, Wu RC, Tsai CL, Lin YH, Alison MR, Hsieh SY, Yu JS, Chiu CT, Yeh CT. (2019) Dynamic bioenergetic alterations in colorectal adenomatous polyps and adenocarcinomas. EBioMedicine. 2019 Jun;44:334-345. doi: 10.1016/j.ebiom.2019.05.031. [PubMed]
  33. Yu J-S. (2019) From discovery of tyrosine phosphorylation to targeted cancer therapies: The 2018 Tang Prize in Biopharmaceutical Science. Biomedical Journal 2019 Apr; 42(2), 80-83 doi: 10.1016/j.bj.2019.03.004. (Invited article) [PubMed]
  34. Chen Y-T*, Tsai C-H, Chen C-L, Yu J-S, Chang Y-H*. (2019) Development of biomarkers of genitourinary cancer using mass spectrometry-based clinical proteomics. J. Food Drug Anal. 2019 Apr; 27(2):387-403. doi: 10.1016/j.jfda.2018.09.005. [PubMed]
  35. Chen Y-T*, Huang H-C, Hsieh Y-J, Fu S-H, Li L, Chen C-L, Chu L-J, Yu J-S. (2019) Targeting amine- and phenol-containing metabolites in urine by dansylation isotope labeling and liquid chromatography mass spectrometry for evaluation of bladder cancer biomarkers. J. Food Drug Anal. 2019 Apr; 27(2): 460-474. doi: 10.1016/ j.jfda.2018.11.008. [PubMed]
  36. Chou PH, Liao WC; Tsai KW, Chen KC Yu JS, Chen TW*. (2019) TACCO, a database connecting transcriptome alterations, pathway alterations and clinical outcomes in cancers. Scientific Reports 2019 Mar 7;9(1):3877. doi: 10.1038/s41598-019-40629-z. [PubMed]
  37. Wang P#, Geng J#, Gao J, Zhao H, Li J, Shi Y, Yang B, Xiao C, Linghu Y, Sun X, Chen X, Hong L, Qin F, Li X, Yu JS, You H, Yuan Z, Zhou D, Johnson RL, Chen L* (2019) Macrophage achieves self-protection against oxidative stress-induced ageing through Mst-Nrf2 axis. Nature Communications 2019 Feb 14;10(1):755. doi: 10.1038/s41467-019-08680-6. [PubMed]
  38. Hsu C-W#, Chen Y-T#, Hsieh Y-J, Chang K-P, Hsueh P-C, Yu J-S, Chang Y-S, Li L*, Wu C-C* (2019) Integrated analyses utilizing metabolomics and transcriptomics reveal perturbation of the polyamine pathway in oral cavity squamous cell carcinoma. Anal Chim Acta 2019 Mar 7;1050:113-122. doi: 10.1016/j.aca.2018.10.070. [PubMed]
  39. Lin Y-H*, Chang H-Y, Wu C-C, Wu C-W, Chang K-P, Yu J-S*. (2019). BRAF protein immunoprecipitation, elution, and digestion from cell extract using a microfluidic mixer for mutant BRAF protein quantification by mass spectrometry. Anal. Bioanal. Chem. 2019 Feb;411(5):1085-1094. doi: 10.1007/s00216-018-1536-2. [PubMed]
  40. Lee C-C#, Hsieh Y-J#, Chen S-W, Fu S-H, Hsu C-W, Wu C-C, Han W, Li Y, Tao H, Chang Y-S, Yu J-S, Li L*, Chang C-H*, Chen Y-T*. (2018) Bretschneider solution-induced alterations in the urine metabolome in cardiac surgery patients. Scientific Reports 2018 Dec 11;8(1):17774. [PubMed]
  41. ●● Liu C-C#, Yu J-S#, Wang P-J, Hsiao Y-C, Liu C-H, Chen Y-C, Lai P-F, Hsu C-P, Fann W-C, Lin C-C*. (2018) Development of sandwich ELISA and lateral flow strip assays for diagnosing clinically significant snakebite in Taiwan. PLOS Neglected Tropical Diseases. 2018 Dec 3;12(12):e0007014. [PubMed] #Contributed equally
  42. Lin W-C, Chakraborty A, Huang S-C, Wang P-Y, Hsieh Y-J, Chien K-Y, Lee Y-H, Chang C-C, Tang H-Y, Lin Y-T, Tung C-S, Luo J-D, Chen T-W, Lin T-Y, Cheng M-L, Chen Y-T, Yeh C-T; Liu J-L, Sung L-Y, Shiao M-S, Yu J-S, Chang Y-S, Pai L-M*. (2018) Histidine-dependent protein methylation is required for compartmentalization of CTP synthase. Cell Reports 2018 Sep 4;24(10):2733-2745.e7. [PubMed]
  43. Wu CP*, Hsieh YJ, Murakami M, Vahedi S, Hsiao SH, Yeh N, Chou AW, Li YQ, Wu YS, Yu JS, Ambudkar SV. (2018) Human ATP-binding cassette transporters ABCB1 and ABCG2 confer resistance to histone deacetylase 6 inhibitor ricolinostat (ACY-1215) in cancer cell lines. Biochem Pharmacol. 2018 Jul 17. 155:316-325. [PubMed]
  44. Liu C-C#, Lin C-C#, Hsiao Y-C, Wang P-J, Yu J-S*. (2018) Proteomic characterization of six Taiwanese snake venoms: Identification of species-specific proteins and development of a SISCAPA-MRM assay for cobra venom factors. J. Proteomics 2018 Sep 15, 187:59-68. [PubMed]
  45. Huang Y-H, Lin K-H, Yu J-S, Wu T-J, Lee W-C, Chao C-K, Pan T-L, Yeh C-T*. (2018) Targeting HSP60 by subcutaneous injections of jetPEI/HSP60-shRNA destabilizes cytoplasmic survivin and inhibits hepatocellular carcinoma growth. Mol. Carcinog. 2018 Apr 19. 57:1087–1101. [PubMed]
  46. Chen C-T, Liu C-C, Yu J-S, Li H-H, Lai M-C*. (2018) Integrated omics profiling identifies hypoxia-regulated genes in HCT116 colon cancer cells J. Proteomics 188:139-151. [PubMed]
  47. ● Chu LJ#, Hsiao YC#, Chiang WF#, Tsai CJ, Lin SY, Chang KP, Chien CY, Yu JS*. (2018) Use of saliva protein biomarkers for diagnosis of oral cavity cancer. International Journal of Head and Neck Science June 2018; 2(2): 56-68. (Invited review article) [Link]
  48. Tsai C-H,#, Chen Y-T*,#, Chang Y-H#, Hsueh C, Liu C-Y, Chang Y-S, Chen C-L*, Yu J-S* (2018) Systematic verification of bladder cancer-associated tissue protein biomarker candidates in urine specimens. Oncotraget 2018 Jul 20;9(56):30731-30747. [PubMed]
  49. Lai YH, Liu H, Chiang WF, Chen TW, Chu LJ, Yu JS, Chen SJ, Chen HC, and Tan BC*. (2018) MiR-31-5p-ACOX1 axis enhances tumorigenic fitness in oral squamous cell carcinoma via the promigratory prostaglandin E2. Theranostics 2018 Jan 1;8(2):486-504. [PubMed]
  50. ●● Hsiao YC#, Chu LJ#, Chen YT, Chi LM, Chien KY, Chiang WF, Chang YT, Chen SF, Wang WS, Chuang YN, Lin SY, Chien CY, Chang KP, Chang YS, and Yu JS*. (2018) Variability assessment of 90 salivary proteins in intra-day and inter-day samples from healthy donors by multiple reaction monitoring-mass spectrometry. (2018) Proteomics-Clin Appl. 2018 Mar;12(2). doi: 10.1002/prca.201700039. [PubMed]
  51. Wu CC#, Lin JD#, Chen JT, Chang CM, Weng HF, Hsueh C, Chien HP and Yu JS*. (2018) Integrated analysis of fine-needle-aspiration cystic fluid proteome, cancer cell secretome, and public transcriptome datasets for papillary thyroid cancer biomarker discovery. Oncotarget 9:12079-12100. [PubMed]
  52. Liu CC, You CH, Yu JS*, Huang GJ, Liu CH, Wang PJ, and Lin CC*. (2017) Analysis of the efficacy of Taiwanese freeze neurotoxic antivenom against Southeast Asian cobra venoms through proteomics and animal model approaches. PLOS Neglected Tropical Disease. 2017 Dec 15;11(12): e0006138. [PubMed]
  53. ●● Hsiao Y-C, Chi L-M, Chien K-Y, Chiang W-F, Chen S-F, Chuang Y-N, Lin S-Y, Wu C-C, Chu LJ, Chen Y-T, Chia S-L, Chien C-Y, Chang K-P, Chang Y-S, and Yu J-S*. (2017) Development of a multiplexed assay for oral cancer candidate biomarkers using peptide immunoaffinity enrichment and targeted mass spectrometry. Mol. Cell. Proteomics 2017 Oct;16(10):1829-1849. [PubMed]
  54. ●● Chen TW#, Lee CC#, Liu H#, Wu CS#, Pickering CR#, Huang PJ, Wang J, Chang IY, Yeh YM, Chen CD, Li HP, Luo JD, Tan BC, Chan TEH, Hsueh C, Chu LJ, Chen YT, Zhang B, Yang CY, Wu CC, Hsu CW, See LC, Tang P, Yu JS, Liao WC, Chiang WF, Rodriguez H, Myers JN, Chang KP*, Chang YS*. (2017) APOBEC3A is an oral cancer prognostic biomarker in carriers of an APOBEC deletion polymorphism. Nature Communications. 2017 Sep 6;8(1):465. [PubMed]
  55. ● Hsiao YC#, Chu LJ#, Chen JT, Yeh TS and Yu JS*. (2017) Proteomic profiling of the cancer cell secretome: informing clinical research. Expert Review of Proteomics (Invited review article) 2017 Sep;14(9):737-756. [PubMed]
  56. ●● Peng Y#, Zhang M#, Zheng L#, Liang Q#, Li H#, Chen J-T, Guo H, Yoshina S, Chen Y-Z, Zhao X, Wu X, Liu B, Mitani S, Yu J-S, Ding Xue*. (2017) Cysteine protease cathepsin B mediates radiation-induced bystander effects. Nature 547(7664), 458–462 (27 July 2017) [PubMed]
  57. Cheng JC*, Tseng CP, Liao MH, Peng CY, Yu JS, Chuang PH, Huang JT, Chen JJW. (2017) Activation of hepatic stellate cells by the ubiquitin C-terminal hydrolase 1 protein secreted from hepatitis C virus-infected hepatocytes. Scientific Reports. 2017 June 30;7:4448. doi:10.1038/s41598-017-04259-7 [PubMed]
  58. ● Hsieh Y-J#, Chien K-Y#, Yang I-F, Lee I-N, Wu C-C, Huang T-Y, and Yu J-S* (2017) Oxidation of protein-bound methionine in Photofrin-photodynamic therapy-treated human tumor cells explored by methionine-containing peptide enrichment and quantitative proteomics approach. Scientific Reports 2017 May 2;7(1):1370. doi: 10.1038/s41598-017-01409-9. [PubMed]
  59. Shao CH, Chen CL, Lin JY, Chen CJ, Fu SH, Chen YT, Chang YS, Yu JS, Tsui KH, Juo CG*, Wu KP*. (2017) Metabolite marker discovery for the detection of bladder cancer by comparative metabolomics. Oncotarget. 2017 Mar 21. 2017; 8:38802-38810 doi: 10.18632/oncotarget.16393. [PubMed]
  60. Chen Y-T*, Chen H-W, Wu C-F, Chu L-J, Chiang W-F, Wu C-C, Yu J-S, Tsai C-H, Liang K-H, Chang Y-S, Wu M, Ou Yang W-T. (2017) Development of a multiplexed LC-MRM/MS method for evaluation of salivary proteins as oral cancer biomarkers. Mol. Cell. Proteomics 2017 May;16(5):799-811. [PubMed]
  61. ● Lin YT, Chien KY, Wu CC, Chang WY, Chu LJ, Yeh CT*, Yu JS*. (2017) Super-SILAC mix coupled with SIM/AIMS assays for targeted verification of phosphopeptides discovered in a large-scale phosphoproteome analysis of hepatocellular carcinoma. J. Proteomics. 2017 Mar 22;157:40-51. [PubMed]
  62. Chung I-C, OuYang C-N, Yuan S-N, Li H-P, Chen J-T, Shieh H-R, Chen Y-J, Ojcius DM, Yu J-S, Chang Y-S, Chen L-C*. (2016) Pyk2 activates the NLRP3 inflammasome by directly phosphorylating ASC and contributes to inflammasome-dependent peritonitis. Scientific Reports 2016 Oct 31; 6:36214. [PubMed]
  63. ●● Yu JS#, Chen YT#, Chiang WF#, Hsiao YC#, Chu LJ#, See LC, Wu CS, Tu HT, Chen HW, Chen CC, Liao WC, Chang YT, Wu CC, Lin CY, Liu SY, Chiou ST, Cha SL, Chang KP, Chien CY, Chang SW, Chang CJ, Young JD, Pao CC, Chang YS*, Hartwell LH* (2016) Saliva Protein Biomarkers to Detect Oral Squamous Cell Carcinoma in a High-Risk Population in Taiwan. Proc Natl Acad Sci USA. 2016 Oct 11;113(41):11549-11554. (#Co-first authors) [PubMed]
  64. Hsu CH, Hsu CW, Hsueh C, Wang CL, Wu YC, Wu CC, Liu CC, Yu JS, Chang YS, Yu CJ.* (2016) Identification and characterization of potential biomarkers by quantitative tissue proteomics of primary lung adenocarcinoma. Mol. Cell. Proteomics 2016 Jul;15(7):2396-410. [PubMed]
  65. ● Chen H#, Hsiao Y-C#, Chiang S-F, Wu C-C, Lin Y-T, Liu H, Zhao H, Chen J-S, Chang Y-S, and Yu J-S*. (2016) Quantitative analysis of wild-type and V600E mutant BRAF proteins in colorectal carcinoma using immunoenrichment and targeted mass spectrometry. Anal. Chim. Acta 2016 Aug 24; 933:144-55. [PubMed]
  66. Wang C-I, Chan Y-Y, Wang C-L, Yu J-S, Chang Y-S, and Yu C-J*. (2016) mTOR regulates proteasomal degradation and Dp1/E2F1-mediated transcription of KPNA2 in lung cancer cells. Oncotarget 2016 May 3;7(18):25432-42. [PubMed]
  67. Wu C-P*, Hsieh Y-J, Hsiao S-H, Su C-Y, Li Y-Q, Huang Y-H, Huang C-W, Hsieh C-H, Yu J-S and Wu Y-S*. (2016) Human ATP-Binding Cassette transporter ABCG2 confers resistance to CUDC-907, a dual inhibitor of histone deacetylase and phosphatidylinositol 3-kinase. Mol. Pharm. 2016 Mar 7;13(3):784-94. [PubMed]

Patent:
  1. Yu JS, Chang KP. (2012) Method of detecting malignancy of nasopharyngeal carcinoma and a nasopharyngeal carcinoma malignancy biomarker. United States Patent, US8,148,059B2, Apr. 3, 2012. Patent period ~
  2. Chen Yiting, Yu Zhaosong, Chen Jianlun, Zhang Yusheng (2013) Biomarkers of bladder cancer and their detection methods. Republic of China Patented Invention No. I390204, patent period: -
  3. Yu Zhaosong, Zhang Yating, Wu Zhiqing, Shi Yiming, Zhang Yusheng (2013) Serum biodetection markers of pancreatic cancer and their applications. Republic of China Patented Invention No. I408370, patent period: ~
  4. Yu Zhaosong, Cai Minghong, Xie Lingling (2014) Plasma biomarkers of distal metastasis of colorectal cancer and its application. Republic of China Patented Invention No. I444386, patent period: ~2032/4/9
  5. Chao-Sung Lai, Jau-Song Yu, Yu-Sun Chang, Po-Lung Yang, Tseng-Fu Lu, Yi-Ting Lin, Wen-Yu Chuang, Ting-Chun Yu, I-Shun Wang, Jyh-Ping Chen, Chou Chien (2014) Surface treatment method by using the NH3 plasma treatment to modify the sensing thin-film. United States Patent, US8741679 B2, June 3, 2014. Patent period 2014/6/3~2032/5/8
  6. Jau-Song Yu, Ya-Ting Chang, Chih-Ching Wu, Yi-Ming Shyr, Yu-Sun Chang (2014) A method for detecting pancreatic cancer using the serological marker ULBP2. European patent, EP2525227B1, Patent period: 2/16 /2015~5/16/2032 (Poland), 11/19/2014~5/16/2032 (France), 12/11/2014~5/16/2032 (Germany), 1/20/2015~5/ 16/2032 (Italy), 11/19/2014~5/16/2032 (United Kingdom), 1/13/2015~5/16/2032 (Spain)
  7. Chen Yiting, Yu Zhaosong, Chen Jianlun, Zhang Yusheng (2016) Urine biomarkers as a predictor of bladder and kidney cancer. Republic of China Patent Invention No. I522367, patent period: 2016/2/21~2033/4/11
  8. Jau-Song Yu, Wei-Fan Chiang, Yi-Ting Chen, Yu-Sun Chang, Lai-Chu See, Yung Chin Hsiao, Kai-Ping Chang. (2016) Apparatus and methods for detecting oral squamous cell carcinoma. US provisional application . No. 62309766 (application date: 2016/03/17)
  9. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2017) Methods for cancer diagnosis and prognosis. International application (PCT) No . PCT/US17/22853 (application date: 2017/03/17)
  10. Yu Zhaosong, Chen Yiting, Jiang Weifan, Xiao Yongjin, Zhang Yusheng, Shi Lizhu, Zhang Kaiping (2019) A method for diagnosing and prognosticating cancer. Republic of China Patent Invention No. I651536, patent period: 2019/2/21~2037/3/15
  11. Err-Cheng Chan, Kuei-Tien Chen, Jau-Song Yu, Yu-Sun Chang Jinn-Shiun Chen. (2017) Serological markers for detecting colorectal cancer and their application for inhibiting colorectal cancer cells. United States Patent, US 9,835,636 B2, Dec. 5, 2017. Patent period: 2011/10/4-2031/10/3
  12. Yu-Sun Chang, Jau-Song Yu, Yi-Ting Chen, Wei-Fan Chiang, Yung Chin Hsiao, Lai-Chu See, Kai-Ping Chang. (2020) Methods for cancer diagnosis and prognosis. European patent, EP3430406B1, Patent period: 2020/12/02~2037/3/17. (application date: 2017/03/17; application No.17767588.1)
  13. Zhang Yating/Yu Zhaosong/Wang Junsheng/Wu Shufang/Chen Zhiru/Liu Yanjun (2021) Matrix metalloproteinase-1 monoclonal antibody, detection kit and detection method thereof (Matrix metalloproteinase-1 monoclonal antibody, detection kit and detection method thereof) Patent of the Republic of China (application number: 109106582, application date 2020/02/27) (examination and approval date 2021/05/14)

Technology transfer and industry-university cooperation:

1. "Related Technologies for Oral Cancer Detection Methods" Gitsuyan Biomedical Co., Ltd., 2017/1/23-2023/1/22. Industry-university cooperation project "Oral cancer biomarker immunoassay reagent development", 2017/6 /1-2020/12/31.

2. "Serum biomarkers for pancreatic cancer and their applications" JIS Yan Biomedical Co., Ltd., 2020/01/10~2030/01/10. "Pancreatic cancer biomarker immune reagent development and testing", 2020/9 /1-2022/8/31.



Awards

Awards or honors
  1. 1995, 1997-2001 National Science Council Grade A Award
  2. 2011 Chang Gung University Research Award
  3. 2017 Chang Gung University Industry-Academia Collaboration Award
  4. 2019 "The 9th Outstanding Alumni of the School of Life Sciences, Tsinghua University"
  5. 2019 Taipei Biotech Awards – Technology Transfer Special Mention Award for “Immuno-based Rapid Test for Detecting the Oral Cancer Biomarker-OCBM-1”
  6. The first place in the 108th Ministry of Science and Technology Corporate Link Industry-Academic Cooperation Outstanding Case Source Award for “Immuno-based Rapid Test for Detecting the Oral Cancer Biomarker-OCBM-1”
  7. 2020 Chang Gung University Industry-Academia Collaboration Award
  8. Outstanding Department Alumni of the Chemistry Department of Cheng Kung University in 110 Years
  9. 110-year National Experimental Research Institute R&D Service Platform Highlight Achievements Award Excellent Work Award---"Oral Cancer/Pancreatic Cancer Detection Methods and Immune Detection Reagents"
  10. 2022 Taiwan Mass Spectrometry Society Outstanding Scholar Research Award

Served as a supervisor of an important society
  1. Director of the 2nd~5th Taiwan Protein Society (2006~2017)
  2. Chairman of the 6th Taiwan Protein Society (2018~2020)
  3. Supervisor of the 7th Taiwan Protein Society (2021~2023)
  4. Director of the Second Taiwan Mass Spectrometry Society (2006/8~2009/7)